K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research In Vitro K6PC-5 (1-10 μM; 24 h) increases the involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs). K6PC-5 promotes differentiation and proliferation of keratinocytes via intracellular Ca 2+ signaling. In addition, K6PC-5 stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase. K6PC-5 (1-10 μM; 24 h) promotes fibroblasts proliferation and collagen synthesis in human fibroblasts. K6PC-5 induces intracellular Ca 2+ concentration ([Ca 2+ ] i ) oscillations in human fibroblasts. K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV-induced infection in EBOV-infected EA.hy926 cells. K6PC-5 significantly reduces the virus titers in supernatants of infected cells and strikingly decreased the amount of VP40 in a concentration-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Normal human epidermal keratinocytes (NHEKs) Concentration: 1 μM, 5 μM, 10 μM Incubation Time: 24 h Result: Increased the involucrin and loricrin levels in a dose-dependent manner. Cell Proliferation AssayCell Line: Human fibroblasts Concentration: 1 μM, 5 μM, 10 μM Incubation Time: 24 h Result: Promoted fibroblast proliferation and procollagen production in human fibroblasts significantly. In Vivo In intrinsically aged hairless mice (56 weeks old), 1% K6PC-5 is applied topically for 2 weeks. This K6PC-5 treatment significantly increases both the number of dermal fibroblasts and collagen production. As a consequence, dermal thickness also increased significantly. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Intrinsically aged hairless mice (56 weeks old)Dosage: 1% (vehicle (PEG:EtOH = 7:3)) Administration: Topical application; twice daily for 2 weeks Result: Enhanced fibroblast proliferation, collagen production, and eventually increased dermal thickness. Form:Solid IC50& Target:SphK1